Loading for you the most updated information... |
Loading for you the most updated information... |
Current pre-clinical cancer animal models are poorly predictive in clinical efficacy, and have limited value in predicting disease indications in humans. Primary tumor tissue offers a valuable resource for biomarker identification, as well as a better alternative for preclinical drug evaluation. However, accessing sufficient high quality tumor tissue remains a significant challenge for translational research. Furthermore, establishing testing systems from primary tumor samples is often cost inhibitive due to low success rate and high labor intensity in the process. CrownBio’s Asian infrastructure and unlimited capacity can JumpStart™ your human primary tumorgraft efficacy testing today!| Tumor Type | Total Cases | P0 | P1 | P2 | P3 |
|---|---|---|---|---|---|
| Adrenal gland | 6 | 1 | 1 | 1 | 1 |
| Brain | 23 | 2 | 2 | 2 | 1 |
| Bile Duct | 3 | 0 | 0 | 0 | 0 |
| Bladder | 20 | 1 | 1 | 1 | 1 |
| Breast | 121 | 2 | 2 | 2 | 2 |
| Testis | 1 | 1 | 0 | 0 | 0 |
| Cervical | 7 | 0 | 0 | 0 | 0 |
| Chondromyxoid Fibroma | 1 | 0 | 0 | 0 | 0 |
| Colorectal | 64 | 28 | 23 | 21 | 21 |
| Endometrial | 6 | 0 | 0 | 0 | 0 |
| Esophageal | 63 | 28 | 28 | 28 | 28 |
| Fallopian | 1 | 1 | 1 | 1 | 1 |
| Gallbladder | 6 | 3 | 3 | 3 | 3 |
| Gastric | 107 | 30 | 30 | 30 | 30 |
| Head and Neck | 99 | 8 | 8 | 7 | 5 |
| Inflammatory Myofibroblastic Tumor | 1 | 0 | 0 | 0 | 0 |
| Kidney | 75 | 3 | 3 | 2 | 2 |
| Liver | 257 | 19 | 15 | 13 | 11 |
| Lung | 218 | 22 | 22 | 17 | 17 |
| Lymphoma | 7 | 1 | 1 | 1 | 1 |
| Mediastinal | 2 | 0 | 0 | 0 | 0 |
| Metastatic Carcinoma | 3 | 3 | 3 | 3 | 3 |
| Ovarian | 27 | 5 | 5 | 4 | 4 |
| Pancreatic | 28 | 6 | 5 | 5 | 3 |
| Prostate | 16 | 1 | 1 | 1 | 1 |
| Sarcoma | 13 | 5 | 5 | 5 | 5 |
| Thymoma | 2 | 0 | 0 | 0 | 0 |
| MIXED | 31 | 1 | 1 | 1 | 1 |
| TOTAL | 1208 | 171 | 160 | 148 | 141 |
In order to provide the highest quality preclinical xenograft service, we have established a set of stringent criteria to validate our in vivo tumor animal models. We guarantee the successful establishment of our validated xenograft models, and will repeat any study without charge if any of our validated tumor lines failed to establish in nude mice.| Cancer type | Cell lines | |
|---|---|---|
| Validated Xenograft Models | ||
| Subcutaneous | Breast | MCF-7(ER neg), MDA-MB-231, SK-BR-3, BT474, MX-1 |
| Prostate | DU-145, PC-3, LNCaP, 22RV1 | |
| Colorectal | HT-29, HCT-116, DLD-1, SW620, LoVo, Colo-205, SW480, Colo-320DM | |
| Lung | A549, NCI-H460, SK-MES-1, NCI-H226, Calu-6, H1975, H1703 | |
| Glioblastoma | U87MG,U118 | |
| Fibrosarcoma | HT-1080 | |
| Pancreatic | Mia-Paca-2, Bx-PC-3, PANC-1, Capan-1, AsPc-1 | |
| Kidney | 786-O, A498 | |
| Liver | HepG2, SK-HEP-1, Hep3B, PLC/PRF/5, HUH-1, HUH-7 | |
| Osteosarcoma | 143B, SJSA-1 | |
| Melanoma | A375, SK-MEL-5, A2058 | |
| Nasopharyngeal | CNE2 | |
| Gastric | MGC803, BGC823, NCI-N87, YCC-2, YCC-16 | |
| Ovarian | SK-OV-3, OVCAR-3 | |
| Leukemia | K562, HL-60, MV-4-11 | |
| Lymphoma | Namalwa, Daudi | |
| Multiple myeloma | RPMI-8226 | |
| Oral cancers | KB | |
| Bladder | 5637 | |
| Epidermoid Carcinoma | A431 | |
| Orthotopic | Breast | BT474, MDA-MB-231 MCF-7(ER pos), MCF-7(her2+), MCF-7 (ER neg), MCF-7-218 (ERpos) |
| Prostate | LNCaP, DU-145 | |
| Lung | A549, H1975,H460 | |
| Glioblastoma | U87MG, LN-229 , U118 | |
| Pancreatic | MiaPaCa-2, PANC-1 | |
| Kidney | 786-O | |
| Liver | HepG2,MHCC97H | |
| Systemic Tumors | Myeloma | RPMI-8226, OPM-2, MM1S, NCI-H929, MM1R |
| Leukemia | HL60, MV-4-11, Molt-4, K562 | |
| Lymphoma | Namalwa, Daudi | |
| Syngeneic Models | ||
| Subcutaneous | Lung | LLC |
| Liver | H22 | |
| Kidney | Renca | |
| Colon | CT-26 | |
| Metastatic | Melanoma | B16F10, B16BL6 |
| Systemic Tumors | Lung | LLC |
| Angiogenesis Models | ||
| Window Chamber | All | Any |
| Matrigel Plug Assay | Lung | A549 |
HuKemia® is the world’s first and only collection of human primary hematological models available for efficacy testing and ex vivo screening. With growing collections of AML, ALL, CLL,CML, Nonhodgkin’s lymphoma, multiple myeloma, mantle cell patient samples, CrownBio extends its translational research platforms for oncology research. Complete with outcome data, these established and validated hematologic models for human leukemias mimic the clinical disease and enable the kinetics, characteristics and chemosensitivity of leukemia to be sequentially monitored in individual immunodeficient mouse model.
| Disease Type | Primary BM Sample | Fit for Efficacy Testing |
|---|---|---|
| AML | 133 | 28 |
| AML | 45 | 18 |
| MM | 51 | 12 |
| CML | 17 | 10 |
| Myelodysplastic syndromes (MDS) | 4 | 0 |
| CLL | 2 | 0 |
| TOTAL | 252 | 68 |
Due to the explosive growth in the more clinical relevant human primary tumorgraft models such as CrownBio’s HuPrime® collection, it is becoming increasingly important to be able to translate the unique profiles of each patient model and its specific tumor attributes into improving clinical trial designs. The HuBase® database, a web-based data-mining platform, is aiming to close this gap by providing expanding depth in the databases contents including ; transcription profiling data, Oncogene SNP data, CNV, mutational status, IHC data sets, clinical histories, tumor growth and passage characteristics, etc. Stay update here or write us to check on your specific gene of interest!
| Tumor Type | Total Sample | IHC | Affy txp profiling | Cancer SNP | Gene mutation | Diagnostic and clinical | SOC data | Growth Data | Whole-genome CNV |
|---|---|---|---|---|---|---|---|---|---|
| Lung Cancer | 11 | 9 | 11 | 11 | 11 | 11 | 3 | 11 | 0 |
| Gastric Cancer | 29 | 24 | 30 | 28 | 29 | 5 | 5 | 29 | 0 |
| Head and Neck Cancer | 4 | 3 | 4 | 3 | 4 | 4 | 1 | 4 | 0 |
| Colorectal Cancer | 20 | 20 | 5 | 4 | 5 | 5 | 3 | 5 | 0 |
| Esophageal Cancer | 22 | 18 | 22 | 19 | 22 | 3 | 2 | 22 | 0 |
| Liver Cancer | 7 | 7 | 7 | 7 | 7 | 4 | 4 | 7 | 0 |
| Kidney Cancer | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ovarian Cancer | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sarcoma | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pancreatic Cancer | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Prostate Cancer | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adrenal Gland Cancer | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphoma | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gall Bladder Cancer | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| TOTAL | 109 | 97 | 79 | 72 | 78 | 32 | 18 | 78 | 0 |
PR_14.pdf (823 Kb) (822 Kb) PR_13.pdf PR_12.pdf (1.26 Mb) PR_11.pdf (804 Kb) PR_10.pdf (809 Kb)We want to meet you! Meet our Experts to discuss their posters, and technology advances. CrownBio often sponsors young investigators, and offers complimentary show passes, so if we are where you want to be, contact us.
Booth: TBD
Special events: Stop by our booth and receive special INTRODUCTORY pricing on a pilot project to put us to your test!
Don't rely on marketing propaganda to invest our critical preclinical projects in, put our scientists to the test. Test our knowledge, push for specific case studies, we will earn your confidence and win your trust!
Special events: We will attend most of the networking events.
Please search us on the Biopartnering website and request a meeting. We are here for you!
Booth: tbd
Watch for our special invitations and promotions dedicated to our current customers at each of the Planet Connect sites.
Booth: tbd
Understanding the pathways and mechanisms which cause cancer and regulate the biological behaviour of tumour cells has lead to the development of numerous new agents and innovative targets for clinical trials.
Booth: TBD
Special events: Contact us now for immediate visibiity and early access to our premier HuKemia® collection of hematologic models.
Check our www.crownbio.com THE BUZZ page to keep updated on the expansion of this newly released asset for accelerating your translational oncology program.If you love the intellectual challenge of working in a fast-paced, results-driven organization, there is a home for you at Crown Biosciences. For consideration of any of the open positions below, simply click on the title and follow the link to upload your cv. If you have any questions for the Human Resources Department, please e-mail hr@crownbio.com .We look forward to meeting you!
CrownBio is an Equal Employment Opportunity employer that values the strength diversity brings to the workplace.
